Continuing PSA screening in older men is common practice but not recommended, highlighting the need for clearer guidance.

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

Rashes are a common side effect of some prostate cancer treatments. Rarely, they may be caused by cancer cells.

Many other conditions can mimic the symptoms of prostate cancer, both in its early or advanced stages. Here's what you need ...

"It’s crucial that patients and their families know about this new option," said Dr. William Russell, an oncology radiologist ...

The MHRA has approved trofolastat to identify how far high-risk prostate cancer has spread before treatment, to detect ...

As a caregiver, I learned that CyberKnife radiation for metastatic prostate cancer comes with psychological and physical ...

Elevated circulating tumor DNA (ctDNA) fraction and tumor suppressor gene loss are associated with worse prognosis in patients with prostate cancer liver metastases (PCLM), accord ...

The Georgetown University Lombardi Comprehensive Cancer Center held a lecture on how certain white blood cells in the immune ...

Guidelines created by a multi-disciplinary panel of specialists focus on implementation of novel treatments and technologies for which level 1 evidence is lacking.

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone and with other drug combinations. The FDA has approved the use of Gozellix, a ...